Shinsuke Sato1, Toshimasa Tsujinaka2, Kazuyoshi Yamamoto3, Tsuyoshi Takahashi4, Kentaro Kishi5, Hiroshi Imamura6, Junya Fujita7, Masakazu Takagi8, Seiichi Hirota9, Toshirou Nishida10. 1. Department of Surgery, Shizuoka General Hospital, 4-27-1 Kitaando, Aoi-ku, Shizuoka, 420-8527, Japan. shinsukesato@gmail.com. 2. Department of Surgery, Kaizuka City Hospital, Osaka, Japan. 3. Department of Surgery, Osaka National Hospital, Osaka, Japan. 4. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. 5. Department of Surgery, Osaka Police Hospital, Osaka, Japan. 6. Department of Surgery, Toyonaka Municipal Hospital, Osaka, Japan. 7. Department of Surgery, NTT West Osaka Hospital, Osaka, Japan. 8. Department of Surgery, Shizuoka General Hospital, 4-27-1 Kitaando, Aoi-ku, Shizuoka, 420-8527, Japan. 9. Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan. 10. Department of Gastric Surgery, National Cancer Center Hospital East, Chiba, Japan.
Abstract
PURPOSE: To investigate the outcomes of a combined treatment regimen comprising primary surgery and tyrosine kinase inhibitor (TKI) therapy for synchronous metastatic gastrointestinal stromal tumors (GIST). METHODS: We analyzed retrospectively 14 cases of synchronous metastatic GIST from the Kinki GIST registry between 2003 and 2007. RESULTS: The primary tumor was located in the stomach, small intestine, and rectum in seven, six, and one patients, respectively. Metastatic tumors developed in the liver, peritoneum, other sites, and multiple organs in three, six, two, and three patients, respectively. The R0 resection rate was 42.9 % and the 5-year overall survival rate was 69.3 %. There was no significant difference in the 5-year overall survival rate between patients who underwent R0/R1 and those who underwent R2 resection (71.4 vs. 68.6 %). There was a strong correlation between survival time from diagnosis and the duration of imatinib therapy (Pearson's correlation coefficient, 0.86; p < 0.001). CONCLUSIONS: Although the role of surgery in the treatment of synchronous metastatic GIST is still unclear, primary surgery as the sole frontline treatment may not have a survival benefit: Continuous TKI therapy is more important for prolonging survival.
PURPOSE: To investigate the outcomes of a combined treatment regimen comprising primary surgery and tyrosine kinase inhibitor (TKI) therapy for synchronous metastatic gastrointestinal stromal tumors (GIST). METHODS: We analyzed retrospectively 14 cases of synchronous metastatic GIST from the Kinki GIST registry between 2003 and 2007. RESULTS: The primary tumor was located in the stomach, small intestine, and rectum in seven, six, and one patients, respectively. Metastatic tumors developed in the liver, peritoneum, other sites, and multiple organs in three, six, two, and three patients, respectively. The R0 resection rate was 42.9 % and the 5-year overall survival rate was 69.3 %. There was no significant difference in the 5-year overall survival rate between patients who underwent R0/R1 and those who underwent R2 resection (71.4 vs. 68.6 %). There was a strong correlation between survival time from diagnosis and the duration of imatinib therapy (Pearson's correlation coefficient, 0.86; p < 0.001). CONCLUSIONS: Although the role of surgery in the treatment of synchronous metastatic GIST is still unclear, primary surgery as the sole frontline treatment may not have a survival benefit: Continuous TKI therapy is more important for prolonging survival.
Authors: Ryan S Turley; Peter D Peng; Srinevas K Reddy; Andrew S Barbas; David A Geller; J Wallis Marsh; Allan Tsung; Timothy M Pawlik; Bryan M Clary Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: Haruyuki Takaki; Tess Litchman; Ann Covey; Franois Cornelis; Majid Maybody; George I Getrajdman; Constantinos T Sofocleous; Karen T Brown; Stephen B Solomon; William Alago; Joseph P Erinjeri Journal: J Gastrointest Cancer Date: 2014-12
Authors: C Mussi; U Ronellenfitsch; J Jakob; E Tamborini; P Reichardt; P G Casali; M Fiore; P Hohenberger; A Gronchi Journal: Ann Oncol Date: 2009-07-23 Impact factor: 32.976
Authors: Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu Journal: J Clin Oncol Date: 2008-02-01 Impact factor: 44.544
Authors: S Bauer; P Rutkowski; P Hohenberger; R Miceli; E Fumagalli; J A Siedlecki; B-P Nguyen; M Kerst; M Fiore; P Nyckowski; M Hoiczyk; A Cats; P G Casali; J Treckmann; F van Coevorden; A Gronchi Journal: Eur J Surg Oncol Date: 2014-01-15 Impact factor: 4.424
Authors: George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar Journal: Lancet Date: 2009-03-18 Impact factor: 79.321